October 26, 2009
Jeffrey B. Davis, Chief Executive Officer of Access Pharmaceuticals, Inc. (OTCBB: ACCP) recently conducted an interview with OneMedPlace.com to discuss recent developments with the company including: reasons Access differentiates itself from other small-cap biotech companies, MuGard launch in Europe and market assessment studies discussions with potential partners about ProLindac, market opportunity for Thiarabine, and the market opportunity for Access’ Cobalamin oral drug delivery technology
Read more »
European launch on target — initial clinician and patient feedback very positive
Dallas, TX, October 15, 2009
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today provided an update on it’s European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. MuGard is commercially launched by Access’ partner, SpePharm, in five European countries, having been granted the CE mark certification in October 2008 with the labeling “prevention and management of the lesions and symptoms of oral mucositis.” SpePharm is currently gathering feedback from clinicians in the UK, Germany and Italy that are participating in a patient assessment project. SpePharm expects that out of a total of approximately 1500 to 2000 patients who will be assessed in this project, a subset of patient forms will be collected by year end, and aggregated clinician and patient feedback will continue to be available on a rolling basis during the fourth quarter 2009 and 2010. Introduction of MuGard into France, Central and Eastern Europe, the Benelux countries and the rest of Europe is anticipated over the next 12 to 18 months.
Read more »
To Launch MuGard Through iMedicor’s Proprietary Alerts System Application
Dallas, TX, October 6, 2009
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced today that it had signed an agreement with iMedicor (OTCBB: VMCI) for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy. Using iMedicor’s highly targeted Alerts System application, initial introduction of MuGard to the 216,000 selected physicians in the US is expected to begin by the end of the year. MuGard is being commercially launched worldwide, with initial launches in the United Kingdom, Germany, Italy, Norway and Greece having been previously announced. Access expects additional commercial launches in Europe, and in the Far East through two partners to start shortly.
Read more »
Business columnist Gene Marcial discusses potential for MuGard
October 2, 2009
Renowned business columnist and author Gene Marcial listed Access Pharmaceuticals, Inc. (OTCBB: ACCP) as one of three promising companies to watch in his latest Inside Wall Street column.
Read more »
Digg!
Del.icio.us
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See